DNA Methylation of Tumor Suppressive miRNAs in Non-Hodgkin’s Lymphomas by Rita Lok-Hay Yim et al.
REVIEW ARTICLE
published: 08 November 2012
doi: 10.3389/fgene.2012.00233
DNA methylation of tumor suppressive miRNAs in
non-Hodgkin’s lymphomas
Rita Lok-HayYim,Yok Lam Kwong, KwanYeungWong and Chor Sang Chim*
Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China
Edited by:
Alexander Pertsemlidis, University of
Texas Health Center at San Antonio,
USA
Reviewed by:
Peng Jin, Emory University School of
Medicine, USA
Maria R. Matarazzo, Institute of
Genetics and Biophysics “ABT” CNR,
Italy
*Correspondence:
Chor Sang Chim, Department of
Medicine, Queen Mary Hospital, The
University of Hong Kong, Room 419,
Block K, Pokfulam Road, Hong Kong,
China.
e-mail: jcschim@hku.hk
DNA methylation is an epigenetic alteration leading to heritable phenotypic changes of cells
with functional consequences. It is important in early embryonic development, stem cell
differentiation, and tissue-specific gene expression. In normal cells, promoter-associated
CpG islands (CGI) are generally unmethylated except in X-chromosome inactivation or
genomic imprinting. In cancer, tumor cells are characterized by global hypomethylation but
locus-specific hypermethylation of promoter-associated CGI, resulting in gene silencing.
MicroRNAs (miRNAs) are short, non-coding RNA sequences of 18–25 nucleotides, which
can repress the translational of multiple protein-coding mRNAs by sequence-specific bind-
ing to the 3′untranslated region. Depending on the genes targeted, miRNA can be tumor
suppressive if an oncogene is repressed, or it can be oncogenic when a tumor suppres-
sive gene is repressed. Recently, aberrant methylation of tumor suppressive miRNAs has
been reported in different types of cancers including lymphomas. Herein, we review the
recent literature of methylation of tumor suppressive miRNAs in different histopathologic
subtypes of lymphomas, and discuss its potential diagnostic, prognostic, and therapeutic
significance.
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LYMPHOMA
Lymphoma results from neoplastic proliferation of lymphocytes.
According to the World Health Organization classification, it can
be broadly classified into Hodgkin and non-Hodgkin lymphomas
(NHL; Swerdlow et al., 2008). Hodgkin lymphoma is characterized
by CD30+ve Reed Sternberg cells with variable degree of reac-
tive cellular infiltrate or sclerosis. NHLs are more heterogeneous,
and are generally classified by the cell lineage, histological pat-
tern, morphology, immunophenotype, or maturity of lymphoma
cells. Based on the lineage of lymphoma cells, NHLs can be clas-
sified as B-, T-, or natural killer (NK)-cell lymphomas. For B-
and T-cell lymphoma, they are further classified as precursor B-
or T-cell lymphoid neoplasms, or mature B- or T-cell neoplasms
(Chan, 2001; Au et al., 2005; Table 1). NHLs often present as nodal
enlargements. However, extranodal sites such as the bone marrow,
liver, spleen, mediastinum (Chim et al., 1996), heart (Chim et al.,
1997), central nervous system, testis, breast, and the gastrointesti-
nal tract can be involved. Moreover, some NHLs present primarily
as extranodal disease. A prominent example is marginal zone B-
cell lymphoma (MZBCL) of the stomach, which is an extranodal
MZBCL of mucosa-associated lymphoid tissue (MALT) frequently
associated with Helicobacter pylori infection of the gastric mucosa
(Chan, 2001). Interestingly, in H. pylori+ve MALT lymphoma of
the stomach, eradication of H. pylori infection alone may lead to
resolution of gastric lymphoma.
Mature B-cell lymphomas can often be conceptually grouped
by the putative maturation ontogeny of the neoplastic cells.
Lymphomas arising from transformation of germinal center B-
cells, which are CD10+ve, include follicular lymphoma (FL),
Burkitt’s lymphoma (BL), and some diffuse large B-cell lymphoma
(DLBCL). DLBCL is the most common form of mature B-cell
lymphoma, comprising about 30% of all NHL. Despite its clin-
ical aggressiveness, with combination chemotherapy, about half
of the patients may be cured. On the other hand, small B-cell
lymphomas comprise FL, small lymphocytic lymphoma (SLL),
MZBCL, BL, lymphoplasmacytic lymphoma, and mantle cell lym-
phoma (MCL). FL is one form of small B-cell lymphoma prevalent
in the Western population, accounting for about 20% of NHL. FL
is characterized by the presence of t (14;18) with upregulation of
BCL2, thereby conferring survival benefit to the lymphoma cells.
It is an indolent disease of the elderly, and often presents with
nodal and advanced stage disease. SLL is the nodal counterpart
of chronic lymphocytic leukemia (CLL), and the tumor B-cells
express dually CD5 and CD23 in addition to pan-B-cell antigens,
CD19, and CD20. MZBCL, another form of indolent, small B-cell
lymphoma, may occur as a nodal or splenic lymphoma in addition
to the extranodal presentation described above.
On the other hand, despite being a form of small B-cell lym-
phoma, BL is an extremely aggressive lymphoma, characterized
histologically by a starry sky appearance with literally all tumor
cells simultaneously engaged in cell proliferation as evidenced by
the almost 100% Ki67 immunoreactivity, and cytogenetically by
t (8;14) in the majority of cases, which leads to upregulation of
the MYC oncogene at 8q24. BL was first discovered in Africa as
an extranodal lymphoma with a high proliferation rate associated
with Epstein–Barr virus (EBV) infection. Subsequently, sporadic
BL, often with extranodal presentation, had been diagnosed in
other parts of the world.
www.frontiersin.org November 2012 | Volume 3 | Article 233 | 1
Yim et al. miRNA methylation in non-Hodgkin’s lymphomas
Table 1 | Major types of mature B-,T-, and NK-cell lymphomas.
MATURE B-CELL NEOPLASMS
Chronic lymphocytic leukemia/small lymphocytic lymphoma
Follicular lymphoma
Extranodal marginal zone lymphoma of mucosa-associated lymphoid
tissue (MALT lymphoma)
Nodal marginal zone lymphoma
Splenic marginal zone lymphoma
Lymphoplasmacytic lymphoma
Mantle cell lymphoma
Plasma cell neoplasms
Burkitt lymphoma
Diffuse large B-cell lymphoma (DLBCL), NOS
Primary mediastinal (thymic) large B-cell lymphoma
DLBCL associated with chronic inflammation
B-cell lymphoma, unclassifiable, with features intermediate between
DLBCL and Burkitt lymphoma
B-cell lymphoma, unclassifiable, with features intermediate between
DLBCL and classical Hodgkin lymphoma
T-cell/histiocyte-rich large B-cell lymphoma
Intravascular large B-cell lymphoma
Plasmablastic lymphoma
Primary effusion lymphoma
MATURET- AND NK-CELL NEOPLASMS
T-cell prolymphocytic leukemia
T-cell large granular lymphocytic leukemia
Peripheral T-cell lymphoma, NOS
Angioimmuoblastic T-cell lymphoma
Anaplastic large cell lymphoma (ALCL), ALK-positive
Anaplastic large cell lymphoma (ALCL), ALK-negative
Extranodal NK/T-cell lymphoma, nasal type
Aggressive NK-cell leukemia
Chronic lymphoproliferative disorders of NK-cells
EBV-positive T-cell lymphoproliferative disorders of childhood
Adult T-cell leukemia/lymphoma
Enteropathy-associated T-cell lymphoma
Hepatosplenic T-cell lymphoma
Subcutaneous panniculitis-like T-cell lymphoma
Mycosis fungoides
Sezary syndrome
Mantle cell lymphoma, once thought to be an indolent small
B-cell lymphoma, is clinically moderately aggressive. It is charac-
terized by t (11;14), leading to the uniform upregulation of cyclin
D1 (Chim et al., 1998). MCL often presents with advanced disease
with involvement of the lymph nodes and frequent extranodal
involvement including spleen, blood, and bone marrow. (Chim
et al., 2003a) With standard therapy, MCL is associated with a
short remission duration with a median overall survival of 4–5
years (Vose, 2012).
It is notable that T-cell lymphoma is much less frequent than
B-cell lymphoma, and depending on the geographic location, it
comprises only 8–15% of all NHLs (Au et al., 2005). Anaplas-
tic large cell lymphoma (ALCL), peripheral T-cell lymphoma,
unspecified, and angioimmunoblastic T-cell lymphoma (AITL)
are the most common forms of mature PTCL (Au et al., 2005).
Most forms of mature T-cell lymphomas are nodal lymphomas. Of
these, the pathology of PTCL, unspecified, were variably described
as T-zone lymphoma, lymphoepithelioid cell lymphoma, pleo-
morphic T-cell lymphoma, small, medium, or large sized types,
and T-immunoblastic lymphoma; so that there was a broad mor-
phologic spectrum and immunophenotypic profiles. On the other
hand,AITL is a disease of the elderly, with the majority being nodal
and advanced stage at presentation. Pathologically, there was a
polymorphic lymphomatous infiltrate admixed with reactive lym-
phocytes, eosinophils, plasma cells, and histiocytes, with arboriz-
ing high endothelial venules. Systemic manifestations includes
hepatosplenomegaly, ascites, proteinuria, and high fever (Chan,
2001; Au et al., 2005). Finally, in ALCL, lymphoma cells are large
and pleomorphic, expressing CD30 in addition to T-cell markers.
ALCL can further be classified by the expression of the anaplas-
tic lymphoma kinase (ALK) into ALK-positive and ALK-negative
subtupes. In ALK-positive ALCL, ALK is often activated as a result
of reciprocal translocation of the ALK gene with another part-
ner gene, with t (2;5) being the prototype that results in fusion of
the nucleophosmin gene with ALK. ALK-positive ALCLs carry a
favorable prognosis compared with ALK-negative ALCLs.
Extranodal NK/T-cell lymphoma, nasal type, is derived puta-
tively from NK-cells which are often CD56-positive. The majority
of NK-cell lymphomas present primarily in the nasal area and
upper aerodigestive tract, and is referred to clinically as nasal
NK-cell lymphomas (Chim et al., 1999, 2004c). Occasionally, NK-
cell lymphomas can arise in extranasal sites, involving the skin,
gastrointestinal tract, salivary glands, and testis, and are referred
to as non-nasal NK-cell lymphomas. Rarely, NK-cell lymphomas
can present in a leukemic phase, and are referred to as NK-cell
leukemia (Kwong, 2005). NK-cell neoplasms are rare but aggres-
sive lymphomas uniformly associated with EBV infection. Patients
with nasal NK-cell lymphoma often present with fever and nasal
symptoms, and locally destructive lesions. Despite the initial nasal
presentation, lymphoma cells may eventually disseminate to other
extranodal sites, which often are the presentation sites of non-
nasal NK-cell lymphomas. Finally, NK-cell leukemia presents with
pancytopenia, bone marrow failure, and is almost always lethal.
miRNA
With complete sequencing of the human genome, an increas-
ing amount of non-coding RNAs (ncRNAs) are unveiled and
shown to work in concert with the protein-coding gene net-
work (Human Genome Sequencing, 2004; Lander, 2011). miRNA,
which is a widely studied subclass of short ncRNAs with a length
of 18–25 nucleotides, leads to translational repression of protein-
coding genes via sequence-specific binding of its seed region to the
3′untranslated region (UTR) of its target protein-coding genes.
Currently more than 1500 miRNAs have been discovered. Inter-
estingly, many miRNAs have been implicated in carcinogenesis
(Kozomara and Griffiths-Jones, 2011). Based on the genomic loca-
tion, miRNA can be classified as intergenic and intragenic. Inter-
genic miRNA is transcribed from non-coding region in between
protein-coding genes, whereas intronic miRNA is encoded in
the intron of, and mostly transcribed in parallel with, its host
protein-coding gene (Lopez-Serra and Esteller, 2012).
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Similar to the transcription of protein-coding genes, most
miRNA genes are also transcribed by RNA polymerase II with the
inclusion of 5′ cap structure and 3′ polyadenylated tail in each of
the primary miRNA (pri-miRNA) transcript (Lee et al., 2004). Pri-
miRNAs, ranging from 100 to 1000 nucleotides in length, are then
processed by a ribonuclease-III DROSHA complex with DGCR8
(DiGeorge Syndrome Critical Region Gene-8) into a stem-looped
precursor miRNA (pre-miRNA; Gregory et al., 2004). These
intermediates pre-miRNAs are exported via Ran-GTP-dependent
exportin-5 (XPO-5) into the cytoplasm, where these pre-miRNA
stem-loops are further processed into mature miRNA duplex (Yi
et al., 2003). Eventually a single-stranded mature miRNA is pro-
duced, ready to function when it is loaded onto the DICER1-TAR
RNA-binding protein-containing RNA-induced silencing com-
plex (RISC; Liu et al., 2004). The biosynthesis and processing of
miRNA is summarized in Figure 1.
Several functional mechanisms of miRNA have been described.
However, the specific binding of miRNA seed region to the
3′UTR of mRNA via imperfect complementarity (Lopez-Serra and
Esteller, 2012) has attracted much attention. Such binding leads to
blockage of protein translation and hence translational silencing
of the target protein-coding gene. Depending on the silenced tar-
get gene, miRNA can also be divided into tumor suppressive and
oncogenic miRNA. A tumor suppressive miRNA targets an onco-
gene while an oncogenic miRNA targets a tumor suppressive gene.
In lymphoma or solid cancers, in which viral infections is involved
in carcinogenesis, potentially oncogenic miRNA may be derived
from the integrated viral genome (Lin et al., 2010; Brown et al.,
2012). Based on miRNA array studies, a multitude of tumor sup-
pressive miRNAs has been shown to be downregulated in different
types of lymphomas (Craig et al., 2011; Dejean et al., 2011; Iqbal
et al., 2012). The primary objective of this article is to review the
intricate role of tumor suppressive miRNAs that are silenced in
lymphoma, and to discuss the emerging role of DNA methylation
in mediating the expression of these miRNAs.
DNA METHYLATION-MEDIATED GENE SILENCING
DNA methylation is an important epigenetic mechanism for cells
to maintain their normal gene expression patterns. Gene methyla-
tion is crucial for genomic imprinting and X-chromosome inacti-
vation for correct tissue and organ development (Reik and Walter,
2001; Kaneda et al., 2004). DNA methylation occurring on CpG
dinucleotides is mediated by DNA methyltransferases (DNMT)1,
3A, and 3B, which add a methyl group to the C5 carbon of the
cytosine residue in the CpG dinucleotides (Okano et al., 1998).
CpG rich regions, known as CpG islands (CGI), can be local-
ized at the promoter region of a protein-coding or miRNA gene.
CGI methylation results in a silencing effect on the associated
protein-coding and miRNA genes. To determine the roles of CGIs
in regulating gene expressions, genome-wide studies have been
conducted to examine the methylation status of CpGs across the
human genome in both normal and cancer cells. An account
of methylation-mediated genomic imprinting and cancer-related
transcriptional silencing is given below (Shen et al., 2007; Choi
et al., 2010; Sandoval et al., 2011).
METHYLATION OF TUMOR SUPPRESSIVE miRNA IN NHL
All articles with the keywords “lymphoma, DNA methylation and
miRNA” obtained from a search of the PubMed were reviewed.
They can be classified into two groups. The first group comprised
FIGURE 1 | Biosynthesis and posttranscriptional processing of miRNA.
Schematic diagram summarizing the biosynthetic pathway and processing of
miRNA to produce a mature miRNA ready to exert it function. RNA Pol II,
RNA polymerase II; DGCR8, DiGeorge syndrome critical region gene-8;
XPO-5, exportin-5; TRBP, TAR-binding protein; RISC, RNA-induced silencing
complex; AGO, Argonaute.
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mechanistic studies of miRNA methylation in special subtypes
of NHL including NK-cell lymphoma (pertaining to miR-146a),
gastric MALT lymphoma (miR-203), t (8;14)-negative BL (miR-9),
and ALK-positive ALCL (miR-29a). The second group comprised
studies of the impact of miRNA methylation in a panel of B-, T-,
or NK-cell lymphomas (Table 2 and Figure 2).
miRNA METHYLATION IN SPECIAL NHL SUBTYPES
miR-146a methylation in NK/T-cell lymphoma
Promoter methylation of miR-146a was described in a study
of primary NK/T-cell lymphoma, which was associated with
downregulation of miR-146a (Paik et al., 2011). Over-expression
of miR-146a was then shown to inhibit lymphoma cell prolif-
eration and induce apoptosis, thereby demonstrating its tumor
suppressor properties. In addition, based on luciferase assay, over-
expression of miR-146a was shown to lead to inhibition of the
NFκB pathway, due to binding to and hence blockage of NFκB
responsive elements, thereby illustrating a role of miR-146 on
NFκB signaling. On the other hand, TNF receptor-associated fac-
tor 6 (TRAF6) has been shown to transactivate the NFκB pathway
by promoting proteasomal degradation of IκB, the inhibitor of
NFκB. By bioinformatic search, TRAF6 was found to possess
Table 2 | Methylated tumor suppressive miRNA common in both lymphoma and other hemic cancers/solid tumors.
miRNA Hematological cancer Solid tumor type Chromosome location
miR-124-1 ALL (Agirre et al., 2012), AML, CLL, myeloma (Wong
et al., 2011)
Cervical (Wilting et al., 2010), colorectal (Lujambio et al.,
2007), liver (Furuta et al., 2010)
8p23.1
miR-203 NHL, MALT lymphoma, DLBCL (Chim et al., 2011b) Liver (Furuta et al., 2010), cervical (Botezatu et al., 2011) 14q32.32
miR-34a NHL, CLL, myeloma (Chim et al., 2010) Melanoma, prostate (Lodygin et al., 2008) 1p36.22
miR-9-1 BL (Onnis et al., 2010) Colorectal (Bandres et al., 2009), breast (Lehmann et al.,
2008), pancreatic (Omura et al., 2008)
1q22
FIGURE 2 | Summary of tumor suppressive functions of miRNA
methylated in lymphoma. Schematic visualization summarizing miRNA
methylated in different subtypes of lymphomas known direct target
oncogenes (solid line) and putative target oncogenes (dotted lines) silenced
by these tumor suppressive miRNA. A key tumor suppressive function of
these miRNA is also summarized.
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miR-146a binding sites at the 3′UTR, to which miR-146a bind-
ing has been demonstrated (Starczynowski et al., 2010). Besides,
the authors showed that downregulation of TRAF6 was achieved
by over-expression of miR-146a, consistent with the notion that
TRAF6 is also a target of miR-146a (Paik et al., 2011). More-
over, downregulation of TRAF6 by siRNA led to inhibition of the
NFκB pathway and consequent downregulation of anti-apoptotic
BCL2, consistent with the notion that miR-146a regulated NFκB
pathway via regulating TRAF6 expression. Furthermore, miR-146a
was shown to confer chemosensitivity of NK lymphoma cells to
etoposide, a chemotherapy active in NK/T-cell lymphoma. Finally,
patients with higher miR-146a expression had better survival than
those with low expression. Therefore, miR-146a is a putative tumor
suppressive miRNA, acting via repression of TRAF6, and hence
downregulation of NFκB signaling. Its frequent hypermethylation
in NK/T-cell lymphoma might be of prognostic significance.
miR-203 methylation gastric MALT lymphoma
A recent study of miRNA expression in H. pylori-positive gastric
MALT lymphoma showed differential expression of miRNA as
compared with normal tonsils. In particular, miR-203 was shown
to be downregulated in lymphoma (Craig et al., 2011), whereas the
adjacent inflammatory but non-lymphoma tissues with chronic
gastritis had higher expression levels. This was biologically rele-
vant, as miR-203 expression was inversely related to the expression
of the miR-203 target gene ABL1. Furthermore, miR-203 was
unmethylated in normal tonsil, minimally methylated in gastri-
tis tissue, but completely methylated in gastric MALT or DLBCL
of stomach, which was derived from transformation of MALT
lymphoma. Therefore, miR-203 methylation appeared specific to
gastric lymphoma, which might have started with chronic gastritis.
The tumor suppressive function of miR-203 was demonstrated in a
mouse model, in which gastric MALT lymphoma developed after
prolonged H. felis infection (Craig et al., 2011). In this model,
miR-203 was highly expressed in normal marginal zone B-cells,
modestly expressed in gastritis tissue and under-expressed in gas-
tric MALT lymphoma tissue with corresponding upregulation of
its target ABL1 proto-oncogene. Over-expression of miR-203 led
to decreased ABL1 mRNA expression and a blockage of Helicobac-
ter antigen-dependent cell proliferation. Finally, treatment with
a tyrosine kinase inhibitor of imatinib that targeted ABL1 led to
regression of gastric tumors (Craig et al., 2011). Therefore, miR-
203 was shown to be a tumor suppressive miRNA targeting ABL1,
and miR-203 methylation might be important in pathogenesis of
MALT lymphoma.
miR-29a methylation in ALK+ve ALCL
A recent study showed that the expression of miR-29a was
suppressed by promoter methylation in ALK-positive ALCL
(Desjobert et al., 2011). Consistent with this observation, the
myeloid cell leukemia 1 (MCL1) gene, a known target of miR-
29a, was highly expressed in ALK-positive ALCL, whereas over-
expression of miR-29a resulted in downregulation of MCL1
(Xiong et al., 2010; Desjobert et al., 2011). Interestingly, miR-
29a expression could be restored either with knockdown of ALK
or its inhibition, suggesting that ALK is involved in miR-29a
methylation. Furthermore, knockdown of ALK or STAT3, known
targets of miR-29a, led to downregulation of DNMT1 and DNMT3
(Desjobert et al., 2011). Therefore, ALK might repress miR-29a via
upregulation of DNMT1 and hence hypermethylation of the miR-
29a promoter. Finally, in a xenograft tumor model of ALK-positive
ALCL, tumors with over-expression of miR-29a were much smaller
that those without. These observations strongly suggested that
miR-29a was a tumor suppressive miRNA hypermethylated in
ALK-positive ALCL.
miR-9-1 methylation in t(8;14)-ve BL
The expression of mature miR-9 from the 3′ arm of the three miR-
9 precursors miR-9-1, miR-9-2, miR-9-3 (derived from different
genomic loci) was low in t (8;14)-negative BL, as compared with
DLBCL or t (8;14)-positive BL, thereby suggesting that miR-9-3p
might be of pathogenetic significance in BL without t (8;14; Onnis
et al., 2010). The low expression of miR-9-3p was found to be
due to DNA hypermethylation of one of the three genomic loci,
miR-9-1. The result was an upregulation of E2F1, a putative target
of miR-9-3p. Since E2F1 is also a transcriptional target of c-MYC,
miR-9-1 methylation with upregulation of E2F1 might be similar
to the biological consequence of t (8;14), where c-MYC dysregu-
lation might also result in excessive transcriptional activation of
E2F1, leading in both instances to unchecked cellular proliferation
(O’Donnell et al., 2005).
miRNA HYPERMETHYLATED IN B-, T-, OR NK-CELL LYMPHOMAS
Based on a candidate miRNA approach, miR-124-1, miR-203, and
miR-34a methylation in B-, T-, and NK-cell lymphomas have been
studied.
miR-124-1 methylation in NHL
miR-124-1 methylation has been studied in a panel of pri-
mary samples of hematological cancers including acute myeloid
leukemia (AML), acute lymphoblastic leukemia (ALL), chronic
myeloid leukemia (CML), CLL, multiple myeloma (MM), and B-
cell, T-cell, and NK-cell NHLs (Wong et al., 2011). In primary sam-
ples at diagnosis, miR-124-1 methylation was absent in CML but
detected in 2% each of MM at diagnosis and relapse/progression;
5% of ALL; 15% of AML; 14% of CLL, and 58.1% of NHL.
Amongst lymphoid malignancies, miR-124-1 was preferentially
methylated in NHL than MM, CLL, or ALL. In primary lymphoma
samples, miR-124-1 was preferentially hypermethylated in B- or
NK/T-cell lymphomas, in which miR-124-1 expression correlated
inversely with miR-124 expression, thereby confirming miRNA
silencing in association with miRNA methylation (Wong et al.,
2011). As chromosome 8p23 is found commonly lost in certain
subtypes of B-cell NHL; frequent miR-124-1 methylation in NHLs
might pose an alternative mechanism of miR-124-1 inactiva-
tion, which may collaborate with miR-124-1 deletion to fulfill the
two-hit Knudson’s hypothesis (Knudson, 2001; Martinez-Climent
et al., 2001; Callet-Bauchu et al., 2005).
miR-203 methylation in NHL
Another study reported the status of miR-203 methylation in 150
patients with various hematological cancers (Chim et al., 2011b).
In primary samples, miR-203 methylation was detected in 5.0% of
ALL, 10.0% of AML, 42.0% of CLL, and 38.8% of NHL (includ-
ing 60.0% of NK, 40.9% of B-cell, and 23.5% of T-cell NHL, and
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hence miR-203 was more frequently hypermethylated in lymphoid
than myeloid malignancies. Amongst the NHL samples studied,
miR-203 was methylated in 40.9% of B-cell NHL, 23.5% of T-
cell NHL, and 60% of NK/T-cell lymphoma. However, there was
no correlation between miR-203 methylation with clinical para-
meters including age, gender, nodal/extranodal presentation, or
Ann Arbor stage. Interestingly, in the patients in which other miR-
NAs were concomitantly studied, miR-203 methylation was found
to be associated with methylation of miR-124-1, miR-34a, and
miR-196b. As both miR-124 and miR-34a target CDK6, the simul-
taneous methylation of these miRNAs might contribute to con-
stitutive activation of certain oncogenic pathways. Alternatively,
inactivation of multiple tumor suppressive miRs targeting multi-
ple pathways might be involved in lymphomagenesis. For instance,
miR-203 methylation might contribute to tumor cell survival
through upregulation of ABL1, and miR-124-1 methylation to pro-
liferative advantage by upregulation of CDK6 (Martinez-Climent
et al., 2001; Craig et al., 2011; Wong et al., 2011).
miR-34a methylation in NHL
Similarly, miR-34a methylation has been studied in a panel of
hematological cancers including 20 ALL, 20 AML, 11 CML, 50
CLL, 55 MM, and 32 NHL patients. In primary samples at diag-
nosis, miR-34a methylation was detected in 4% of CLL, 5.5% of
MM, and 18.8% of NHL at diagnosis, but not in ALL, AML, and
CML (Chim et al., 2010). Amongst lymphoid malignancies, miR-
34a was preferentially methylated in NHL, in particular NK/T-cell
lymphoma. The findings suggested that mechanisms controlling
the expression of a miRNA are cancer dependent, although miRNA
might exert its tumor suppressive function in a similar mechanistic
action in lymphoma of different subtypes.
DISCUSSION
Based on the above summary, a few points are worth further
discussion.
Firstly, while mechanistic studies have been performed to illus-
trate the role of miR methylation in the pathogenesis of certain
lymphoma subtypes (such as methylation of miR-146a in NK-cell
lymphoma, miR-230 in gastric MALT lymphoma, and miR-29a in
ALK+ve ALCL), it is likely that multiple miRs may be hypermethy-
lated in any single lymphoma subtype. For instance, miR-203 have
been shown to be hypermethylated in a multitude of hematolog-
ical cancers especially CML and Ph+ve ALL (Bueno et al., 2008),
and hence not restricted to gastric MALT lymphoma. This was fur-
ther illustrated by our work that showed miR-203 methylation in
multiple lymphoid malignancies including B-CLL, and B-cell, T-
cell and even NK-cell lymphoma (Chim et al., 2011b). Therefore,
multiple miRs are likely hypermethylated in a lymphoma subtype,
and hence a lymphoma type-specific miR methylation profiles.
Secondly, miR-146a was shown hypermethylated in NK-cell
lymphoma associated with upregulation of NFkB pathway (Paik
et al., 2011). However, based on a candidate gene approach, mul-
tiple miRs have been shown to be hypermethylated in NK-cell
lymphoma too. For instance, miR-34a, -203, and -124-1 were fre-
quently methylated in NK-cell lymphomas (Chim et al., 2010,
2011a; Wong et al., 2011). Moreover, a recent miR array study
of nasal NK-cell lymphoma showed that multiple miRs were
downregulated in NK-cell lymphoma including miR-101, miR-
26a, miR26b, miR-28-5, and miR-363 (Ng et al., 2011). Therefore,
methylation may occur in multiple miR promoter-associated CGI,
regulating multiple signaling pathways including NFkB.
Thirdly, while some of these reported miRNAs, such as miR-
9-1, 124-1, and -203, are embedded in classical CGI with proven
promoter activities, some miRNAs were reported to be hyperme-
thylated at scanty CpG sites upstream of the respective miRNA. For
instance, miR-29a was postulated to be regulated by a stretch of 5
CpG sites at 1.1 kb upstream of its precursor sequence (Desjobert
et al., 2011). Similarly, miR-146a was suggested to be regulated by
two sparsely separated CpG dinucleotides immediately upstream
of its precursor sequence, instead of the defined primary sequence
(Paik et al., 2011). Last but not least, as DNMT has been shown
to be the translational target of miR-29 family miRs, it would
be interesting to see if restoration of miR-29a in hypermethy-
lated cell lines may lead to re-expression of methylation-silenced
tumor suppressor genes in addition to downregulation of DNMT
family genes. For instance, miR-29b restoration in AML cells led
to global DNA hypomethylation, resulting in re-expression of
CDKN2B and estrogen receptor 1 (ESR1) through promoter DNA
hypomethylation (Garzon et al., 2009). Moreover, in lung can-
cer, miR-29 family miRs (29a, 29b, and 29c) directly target both
DNMT3A and -3B, and over-expression of miR-29s in lung cancer
cell lines restores normal patterns of DNA methylation, induces
re-expression of methylation-silenced tumor suppressor genes and
inhibits tumorigenicity in vitro and in vivo (Fabbri et al., 2007).
In conclusion, there is much to be learned of miR methy-
lation in NHL regarding the biology, pattern and its role in
lymphomagenesis.
CONCLUSION AND FUTURE PERSPECTIVE
In conclusion, the pathogenetic role of miRNAs methylation in
lymphomagenesis is just beginning to be unraveled. In contrast,
there is considerable data to show that inactivation of tumor sup-
pressor genes by DNA methylation plays important roles in the
pathogenesis and prognostification of hematological malignan-
cies (Chim et al., 2001a,b, 2003b, 2004a,b, 2005a,b). For instance,
methylation of retinoic acid receptor alpha (RARA), PTPN6,
and DAPK genes has been implicated in pathogenesis of AML,
myeloma, and CLL respectively (Reik and Walter, 2001; Chim
et al., 2002, 2006; Kaneda et al., 2004). Moreover, methylation of
CDKN2B and WNT inhibitory factor 1 (WIF1) has been shown to
be an independent prognostic factor predicting inferior disease-
free survival in acute promyelocytic leukemia (Chim et al., 2001b,
2003b, 2005a). Therefore, future studies will help to confirm the
pathogenetic and prognostic impact of miRNA methylation in
NHLs.
DNA methylation can be reversed by demethylating agents
5-azacytidine or decitabine, and therapeutic benefits have been
demonstrated in patients with myelodysplastic syndrome (Garcia-
Manero and Fenaux, 2011). Besides, histone deacetylase inhibitors
including vorinostat and panobinostat (Duvic and Vu, 2007),
have been shown to be effective for some forms of lymphoma
such as mycosis fungoides. As 5-azacytidine or decitabine may
act synergistically with histone deacetylase inhibitors to enhance
re-expression of genes silenced by hypermethylation, this strategy
Frontiers in Genetics | Non-Coding RNA November 2012 | Volume 3 | Article 233 | 6
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might also be applied to miRNA hypermethylation. Finally, there is
hope that downregulated tumor suppressor miRNA in cancer may
be restored by the use of miRNA mimics (Henry et al., 2011), which
can form a partially double-stranded RNA mimicking endogenous
pre-miRNA to be processed into an active miRNA molecule (Calin
and Croce,2009). miRNA can be delivered to the tumor in the form
of an oligonucleotide mimic or by expressing the miRNA in the
cancer using a gene vector (Henry et al., 2011).
REFERENCES
Agirre, X., Martinez-Climent, J. A.,
Odero, M. D., and Prosper, F. (2012).
Epigenetic regulation of miRNA
genes in acute leukemia. Leukemia
26, 395–403.
Au, W.-Y., Ma, S.-Y., Chim, C.-S., Choy,
C., Loong, F., Lie, A. K. W., et al.
(2005). Clinicopathologic features
and treatment outcome of mature
T-cell and natural killer-cell lym-
phomas diagnosed according to the
world health organization classifica-
tion scheme: a single center expe-
rience of 10 years. Ann. Oncol. 16,
206–214.
Bandres, E., Agirre, X., Bitarte, N.,
Ramirez, N., Zarate, R., Roman-
Gomez, J., et al. (2009). Epigenetic
regulation of microRNA expression
in colorectal cancer. Int. J. Cancer
125, 2737–2743.
Botezatu, A., Goia-Rusanu, C. D.,
Iancu, I. V., Huica, I., Plesa, A.,
Socolov, D., et al. (2011). Quan-
titative analysis of the relationship
between microRNA-124a, -34b and
-203 gene methylation and cervi-
cal oncogenesis. Mol. Med. Rep. 4,
121–128.
Brown, A. C., Nair, V., and Allday, M. J.
(2012). Epigenetic regulation of the
latency-associated region of Marek’s
disease virus in tumor-derived T-
cell lines and primary lymphoma. J.
Virol. 86, 1683–1695.
Bueno, M. J., Pérez De Castro, I., Gómez
De Cedrón, M., Santos, J., Calin, G.
A., Cigudosa Juan, C., et al. (2008).
Genetic and epigenetic silencing
of microRNA-203 enhances ABL1
and BCR-ABL1 oncogene expres-
sion. Cancer Cell 13, 496–506.
Calin, G. A., and Croce, C. M. (2009).
Chronic lymphocytic leukemia:
interplay between noncoding RNAs
and protein-coding genes. Blood
114, 4761–4770.
Callet-Bauchu, E., Baseggio, L., Fel-
man, P., Traverse-Glehen, A., Berger,
F., Morel, D., et al. (2005). Cyto-
genetic analysis delineates a spec-
trum of chromosomal changes that
can distinguish non-MALT mar-
ginal zone B-cell lymphomas among
mature B-cell entities: a descrip-
tion of 103 cases. Leukemia 19,
1818–1823.
Chan, J. K. C. (2001). The new world
health organization classification of
lymphomas: the past, the present
and the future. Hematol. Oncol. 19,
129–150.
Chim, C. S., Chan, A. C. L., Choo, C. K.,
Kwong,Y. L., Lie,A. K. W., and Liang,
R. (1998). Mantle cell lymphoma in
the Chinese: clinicopathological fea-
tures and treatment outcome. Am. J.
Hematol. 59, 295–301.
Chim, C. S., Chan, A. C. L., Kwong, Y. L.,
and Liang, R. (1997). Primary car-
diac lymphoma. Am. J. Hematol. 54,
79–83.
Chim, C. S., Fung, T. K., Wong, K.
F., Lau, J. S., and Liang, R. (2006).
Frequent DAP kinase but not p14
or Apaf-1 hypermethylation in B-
cell chronic lymphocytic leukemia.
J. Hum. Genet. 51, 832–838.
Chim, C. S., Hu, W. H. C., Loong, F.,
Ooi, G. C., and Liang, R. (2003a).
GI manifestations of mantle cell
lymphoma. Gastrointest. Endosc. 58,
931–933.
Chim, C. S., Wong, S. Y., and Kwong,
Y. L. (2003b). Aberrant gene pro-
moter methylation in acute promye-
locytic leukaemia: profile and prog-
nostic significance. Br. J. Haematol.
122, 571–578.
Chim, C. S., Lau, J. S., Wong, K.
F., and Kwong, Y. L. (2005a).
CDKN2B methylation is an inde-
pendent poor prognostic factor in
newly diagnosed acute promye-
locytic leukemia. Leukemia 20,
149–151.
Chim, C. S., Wong, S. Y., Pang, A., Chu,
P., Lau, J. S., Wong, K. F., et al.
(2005b). Aberrant promoter methy-
lation of the retinoic acid recep-
tor alpha gene in acute promye-
locytic leukemia. Leukemia 19,
2241–2246.
Chim, C. S., Liang, R., Chan, A. C. L.,
Kwong, Y. L., Ho, F. C. S., and Todd,
D. (1996). Primary B cell lymphoma
of the mediastinum. Hematol. Oncol.
14, 173–179.
Chim, C.-S., Ma, S.-Y., Au, W.-Y., Choy,
C., Lie, A. K. W., Liang, R., et al.
(2004a). Primary nasal natural killer
cell lymphoma: long-term treat-
ment outcome and relationship with
the international prognostic index.
Blood 103, 216–221.
Chim, C. S., Fung, T. K., Cheung, W.
C., Liang, R., and Kwong, Y. L.
(2004b). SOCS1 and SHP1 hyper-
methylation in multiple myeloma:
implications for epigenetic activa-
tion of the Jak/STAT pathway. Blood
103, 4630–4635.
Chim, C. S., Ma, S. Y., Au, W. Y., Choy,
C., Lie, A. K. W., Liang, R., et al.
(2004c). Primary nasal natural killer
cell lymphoma: long-term treat-
ment outcome and relationship with
the international prognostic index.
Blood 103, 216–221.
Chim, C. S., Ooi, G. C., Shek, T. W.
H., Liang, R., and Kwong, Y. L.
(1999). Lethal midline granuloma
revisited: nasal T/natural-killer cell
lymphoma. J. Clin. Oncol. 17, 1322.
Chim, C. S., Tam, C. Y., Liang, R.,
and Kwong, Y. L. (2001a). Methyla-
tion of p15 and p16 genes in adult
acute leukemia: lack of prognostic
significance. Cancer 15, 2222–2229.
Chim, C. S., Liang, R., Tam, C. Y.
Y., and Kwong, Y. L. (2001b).
Methylation of p15 and p16 genes
in acute promyelocytic leukemia:
potential diagnostic and prognos-
tic significance. J. Clin. Oncol. 19,
2033–2040.
Chim, C. S., Wan, T., Wong, K. Y., Fung,
T. K., Drexler, H., and Wong, K.
F. (2011a). Methylation of miR-34a,
miR-34b/c, miR-124-1 and miR-
203 in Ph-negative myeloprolifera-
tive neoplasms. J. Transl. Med. 9,
197.
Chim, C. S., Wong, K. Y., Leung, C. Y.,
Chung, L. P., Hui, P. K., Chan, S. Y., et
al. (2011b). Epigenetic inactivation
of the hsa-miR-203 in haematolog-
ical malignancies. J. Cell. Mol. Med.
15, 2760–2767.
Chim, C. S., Wong, A. S. Y., and Kwong,
Y. L. (2002). Infrequent hypermethy-
lation of CEBPA promotor in acute
myeloid leukaemia. Br. J. Haematol.
119, 988–990.
Chim,C. S.,Wong,K.Y.,Qi,Y.,Loong,F.,
Lam,W. L.,Wong, L. G., et al. (2010).
Epigenetic inactivation of the miR-
34a in hematological malignancies.
Carcinogenesis 31, 745–750.
Choi, J.-H., Li, Y., Guo, J., Pei,
L., Rauch, T. A., Kramer, R.
S., et al. (2010). Genome-wide
DNA methylation maps in follic-
ular lymphoma cells determined
by methylation-enriched bisulfite
sequencing. PLoS ONE 5, e13020.
doi:10.1371/journal.pone.0013020
Craig, V. J., Cogliatti, S. B., Rehrauer, H.,
Wündisch, T., and Müller, A. (2011).
Epigenetic silencing of microRNA-
203 dysregulates ABL1 expression
and drives helicobacter-associated
gastric lymphomagenesis. Cancer
Res. 71, 3616–3624.
Dejean, E., Renalier, M. H., Foisseau, M.,
Agirre, X., Joseph, N., De Paiva, G. R.,
et al. (2011). Hypoxia-microRNA-
16 downregulation induces VEGF
expression in anaplastic lymphoma
kinase (ALK)-positive anaplastic
large-cell lymphomas. Leukemia 25,
1882–1890.
Desjobert, C., Renalier, M.-H., Bergalet,
J., Dejean, E., Joseph, N., Kruczyn-
ski, A., et al. (2011). MiR-29a
down-regulation in ALK-positive
anaplastic large cell lymphomas
contributes to apoptosis block-
ade through MCL-1 overexpression.
Blood 117, 6627–6637.
Duvic, M., and Vu, J. (2007). Vorinos-
tat in cutaneous T-cell lymphoma.
Drugs Today 43, 585.
Fabbri, M., Garzon, R., Cimmino, A.,
Liu, Z., Zanesi, N., Callegari, E., et al.
(2007). MicroRNA-29 family reverts
aberrant methylation in lung can-
cer by targeting DNA methyltrans-
ferases 3A and 3B. Proc. Natl. Acad.
Sci. U.S.A. 104, 15805–15810.
Furuta, M., Kozaki, K.-I., Tanaka, S.,
Arii, S., Imoto, I., and Inazawa,
J. (2010). miR-124 and miR-203
are epigenetically silenced tumor-
suppressive microRNAs in hepato-
cellular carcinoma. Carcinogenesis
31, 766–776.
Garcia-Manero, G., and Fenaux, P.
(2011). Hypomethylating agents and
other novel strategies in myelodys-
plastic syndromes. J. Clin. Oncol. 29,
516–523.
Garzon, R., Liu, S., Fabbri, M., Liu, Z.,
Heaphy, C. E. A., Callegari, E., et
al. (2009). MicroRNA-29b induces
global DNA hypomethylation and
tumor suppressor gene reexpression
in acute myeloid leukemia by tar-
geting directly DNMT3A and 3B
and indirectly DNMT1. Blood 113,
6411–6418.
Gregory, R. I., Yan, K.-P., Amuthan,
G., Chendrimada, T., Doratotaj, B.,
Cooch, N., et al. (2004). The Micro-
processor complex mediates the gen-
esis of microRNAs. Nature 432,
235–240.
Henry, J., Azevedo-Pouly, A., and
Schmittgen, T. (2011). MicroRNA
replacement therapy for cancer.
Pharm. Res. 28, 3030–3042.
Human Genome Sequencing, C. (2004).
Finishing the euchromatic sequence
of the human genome. Nature 431,
931–945.
Iqbal, J., Shen, Y., Liu, Y., Fu, K., Jaffe,
E. S., Liu, C., et al. (2012). Genome-
wide miRNA profiling of mantle cell
lymphoma reveals a distinct sub-
group with poor prognosis. Blood
119, 4939–4948.
www.frontiersin.org November 2012 | Volume 3 | Article 233 | 7
Yim et al. miRNA methylation in non-Hodgkin’s lymphomas
Kaneda, M., Okano, M., Hata, K., Sado,
T., Tsujimoto, N., Li, E., et al. (2004).
Essential role for de novo DNA
methyltransferase Dnmt3a in pater-
nal and maternal imprinting. Nature
429, 900–903.
Knudson, A. G. (2001). Two genetic hits
(more or less) to cancer. Nat. Rev.
Cancer 1, 157–162.
Kozomara, A., and Griffiths-Jones,
S. (2011). miRBase: integrating
microRNA annotation and deep-
sequencing data. Nucleic Acids Res.
39, D152–D157.
Kwong, Y. L. (2005). Natural killer-cell
malignancies: diagnosis and treat-
ment. Leukemia 19, 2186–2194.
Lander, E. S. (2011). Initial impact of the
sequencing of the human genome.
Nature 470, 187–197.
Lee, Y., Kim, M., Han, J., Yeom, K.-H.,
Lee, S., Baek, S. H., et al. (2004).
MicroRNA genes are transcribed by
RNA polymerase II. EMBO J. 23,
4051–4060.
Lehmann, U., Hasemeier, B., Christgen,
M., Müller, M., Römermann, D.,
Länger, F., et al. (2008). Epige-
netic inactivation of microRNA
gene hsa-mir-9-1 in human
breast cancer. J. Pathol. 214,
17–24.
Lin, Y.-T., Kincaid, R. P., Arasappan,
D., Dowd, S. E., Hunicke-Smith,
S. P., and Sullivan, C. S. (2010).
Small RNA profiling reveals anti-
sense transcription throughout the
KSHV genome and novel small
RNAs. RNA 16, 1540–1558.
Liu, J., Carmell, M. A., Rivas, F.
V., Marsden, C. G., Thomson, J.
M., Song, J.-J., et al. (2004). Arg-
onaute2 is the catalytic engine
of mammalian RNAi. Science 305,
1437–1441.
Lodygin, D., Tarasov, V., Epanchintsev,
A., Berking, C., Knyazeva, T., Körner,
H., et al. (2008). Inactivation of miR-
34a by aberrant CpG methylation in
multiple types of cancer. Cell Cycle
7, 2591–2600.
Lopez-Serra, P., and Esteller, M. (2012).
DNA methylation-associated
silencing of tumor-suppressor
microRNAs in cancer. Oncogene 31,
1609–1622.
Lujambio, A., Ropero, S., Ballestar, E.,
Fraga, M. F., Cerrato, C., Setién, F., et
al. (2007). Genetic unmasking of an
epigenetically silenced microRNA in
human cancer cells. Cancer Res. 67,
1424–1429.
Martinez-Climent, J. A., Vizcarra, E.,
Sanchez, D., Blesa, D., Marugan, I.,
Benet, I., et al. (2001). Loss of a
novel tumor suppressor gene locus
at chromosome 8p is associated with
leukemic mantle cell lymphoma.
Blood 98, 3479–3482.
Ng, S.-B., Yan, J., Huang, G., Selvara-
jan, V., Tay, J. L.-S., Lin, B., et
al. (2011). Dysregulated microRNAs
affect pathways and targets of bio-
logic relevance in nasal-type natural
killer/T-cell lymphoma. Blood 118,
4919–4929.
O’Donnell, K. A., Wentzel, E. A., Zeller,
K. I., Dang, C. V., and Mendell, J.
T. (2005). c-Myc-regulated microR-
NAs modulate E2F1 expression.
Nature 435, 839–843.
Okano, M., Xie, S., and Li, E. (1998).
Cloning and characterization of a
family of novel mammalian DNA
(cytosine-5) methyltransferases.
Nat. Genet. 19, 219–220.
Omura, N., Li, C.-P., Li, A., Hong, S.-M.,
Walter, K., Jimeno, A., et al. (2008).
Genome-wide profiling at methy-
lated promoters in pancreatic ade-
nocarcinoma. Cancer Biol. Ther. 7,
1146–1156.
Onnis, A., De Falco, G., Antonicelli, G.,
Onorati, M., Bellan, C., Sherman, O.,
et al. (2010). Alteration of microR-
NAS regulated by c-myc in burkitt
lymphoma. PLoS ONE 5, e12960.
doi:10.1371/journal.pone.0012960
Paik, J. H., Jang, J.-Y., Jeon, Y. K.,
Kim, W. Y., Kim, T. M., Heo, D.
S., et al. (2011). MicroRNA-146a
downregulates NFκB activity via
targeting TRAF6 and functions as
a tumor suppressor having strong
prognostic implications in NK/T
Cell lymphoma. Clin. Cancer Res. 17,
4761–4771.
Reik, W., and Walter, J. (2001). Genomic
imprinting: parental influence on
the genome. Nat. Rev. Genet. 2,
21–32.
Sandoval, J., Heyn, H., Moran, S., Serra-
Musach, J., Pujana, M. A., Bibikova,
M., et al. (2011).Validation of a DNA
methylation microarray for 450,000
CpG sites in the human genome.
Epigenetics 6, 692–702.
Shen, L., Kondo, Y., Guo, Y., Zhang,
J., Zhang, L., Ahmed, S., et al.
(2007). Genome-wide profiling of
DNA methylation reveals a class
of normally methylated CpG island
promoters. PLoS Genet. 3, e181.
doi:10.1371/journal.pgen.0030181
Starczynowski, D. T., Kuchenbauer, F.,
Argiropoulos, B., Sung, S., Morin,
R., Muranyi, A., et al. (2010). Iden-
tification of miR-145 and miR-
146a as mediators of the 5q- syn-
drome phenotype. Nat. Med. 16,
49–58.
Swerdlow, S. H., Campo, E., Harris, N.
L., Jaffe, E. S., Pileri, S. A., Stein,
H., et al. (2008). WHO Classifica-
tion of Tumours of Haematopoietic
and Lymphoid Tissues. Lyon: Inter-
national Agency for Research on
Cancer.
Vose, J. M. (2012). Mantle cell lym-
phoma: 2012 update on diagno-
sis, risk-stratification, and clinical
management. Am. J. Hematol. 87,
604–609.
Wilting, S., Van Boerdonk, R., Henken,
F., Meijer, C., Diosdado, B., Mei-
jer, G., et al. (2010). Methylation-
mediated silencing and tumour
suppressive function of hsa-miR-
124 in cervical cancer. Mol. Cancer
9, 167.
Wong, K. Y., So, C. C., Loong, F., Chung,
L. P., Lam, W. W. L., Liang, R., et
al. (2011). Epigenetic inactivation
of the miR-124-1 in haematological
malignancies. PLoS ONE 6, e19027.
doi:10.1371/journal.pone.0019027
Xiong, Y., Fang, J.-H., Yun, J.-P., Yang,
J., Zhang, Y., Jia, W.-H., et al. (2010).
Effects of microRNA-29 on apopto-
sis, tumorigenicity, and prognosis of
hepatocellular carcinoma. Hepatol-
ogy 51, 836–845.
Yi, R., Qin, Y., Macara, I. G., and
Cullen, B. R. (2003). Exportin-5
mediates the nuclear export of pre-
microRNAs and short hairpin RNAs.
Genes Dev. 17, 3011–3016.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or financial relationships that
could be construed as a potential con-
flict of interest.
Received: 12 July 2012; accepted: 15 Octo-
ber 2012; published online: 08 November
2012.
Citation: Yim RL-H, Kwong YL, Wong
KY and Chim CS (2012) DNA methy-
lation of tumor suppressive miRNAs in
non-Hodgkin’s lymphomas. Front. Gene.
3:233. doi: 10.3389/fgene.2012.00233
This article was submitted to Frontiers in
Non-Coding RNA, a specialty of Frontiers
in Genetics.
Copyright © 2012 Yim, Kwong , Wong
and Chim. This is an open-access arti-
cle distributed under the terms of the
Creative Commons Attribution License,
which permits use, distribution and
reproduction in other forums, provided
the original authors and source are cred-
ited and subject to any copyright notices
concerning any third-party graphics etc.
Frontiers in Genetics | Non-Coding RNA November 2012 | Volume 3 | Article 233 | 8
